Stock IMNM IMMUNOME, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Immunome, Inc.

Equities

IMNM

US45257U1088

Real-time Estimate Cboe BZX
Other stock markets
 02:43:00 2024-05-06 pm EDT 		5-day change 1st Jan Change
15.38 USD -2.32% Intraday chart for Immunome, Inc. +11.51% +44.02%
May. 02 Immunome, Inc. Appoints Kinney Horn as Chief Business Officer CI
Apr. 30 JPMorgan Starts Immunome With Overweight Rating, $24 Price Target MT

Evolution of the average Target Price on Immunome, Inc.

Price target over the last 5 years

History of analyst recommendation changes

0dea64db89ed6168a2c1d.dKLMWpGhJqQPFaFkxWOp6LGmqWrxBoXB_mCZMF7QzoU.Bu3_FeDUFOA8f8hJiCHArN_j3A2QfrCRlS76diSjo91H44geofBj6ntn-A~8602f072145708380e46677dae01e2b1

Analyst Recommendations on Immunome, Inc.

JPMorgan Starts Immunome With Overweight Rating, $24 Price Target MT
Guggenheim Starts Immunome With Buy Rating, $35 Price Target MT
Wedbush Adjusts Immunome's Price Target to $33 From $27, Maintains Outperform Rating MT
Wedbush Raises Immunome's PT to $27 From $19 on Heels of Announced Plans to Acquire AL101, AL102 From Ayala Pharmaceuticals; Keeps Outperform Rating MT
Wedbush Raises Immunome's PT to $19 From $12 After Acquiring IM-1021 From Zentalis Pharmaceuticals, Maintains Outperform Rating MT
Immunome Shares Rise After Wedbush Starts Coverage With outperform Rating MT
Wedbush Starts Immunome With Outperform Rating, $12 Price Target; Has Positive View for Early-Stage Pipeline of Targeted Cancer Therapies MT
Chardan Cuts Price Target on Immunome to $8 From $9, Maintains Buy Rating MT
Cantor Fitzgerald Initiates Immunome's Coverage With Overweight Rating, Sets Price Target at $8 MT
Chardan Adjusts Immunome's Price Target to $9 From $16, Citing IMM-BCP-01 Launch Expectations, Stock Dilution From Future Capital Raises; Buy Rating Kept MT
Cantor Fitzgerald Starts Immunome at Overweight with $35 Price Target MT
IMMUNOME : Chardan Adjusts Price Target on Immunome to $21 From $18 on Q2 Update, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
15.75 USD
Average target price
32.5 USD
Spread / Average Target
+106.35%
High Price Target
38 USD
Spread / Highest target
+141.27%
Low Price Target
24 USD
Spread / Lowest Target
+52.38%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Immunome, Inc.

JPMorgan Chase
Guggenheim
Wedbush
Chardan Research
Cantor Fitzgerald
Chardan

Ratings for Immunome, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. IMNM Stock
  4. Consensus Immunome, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW